ArticleBlood cancer journal2023

Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency.

Gian Matteo Rigolin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.